RxDoctor Payments Data

Amanda Hobbs, NP

Family · Vidalia, GANPI 1750880373

Payments from drug & device makers

$3,498in general payments, 2019–2025

Across 191 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$511
  • LEO Pharma Inc.$271
  • Regeneron Healthcare Solutions, Inc.$267
  • Sun Pharmaceutical Industries Inc.$247
  • UCB, Inc.$213
  • plus $951 from 9 others

What the payments were for

  • Food & beverage$3,38197%
  • Education$1173%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,498 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$48,841
Medicare patients
261
Services billed
1,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab43$430,212
Skyrizi PenRisankizumab-Rzaa16$342,648
Taltz AutoinjectorIxekizumab33$212,861
TremfyaGuselkumab11$153,462
Dupixent PenDupilumab37$150,098
Cosentyx (2 Syringes)Secukinumab14$100,997
Enbrel SureclickEtanercept11$79,408
Triamcinolone Acetonide183$2,149
Clindamycin Phosphate57$1,972
Dapsone23$1,842
Fluocinonide54$1,755
Alclometasone Dipropionate46$1,747
Betamethasone Dipropionate37$1,713
Doxycycline Hyclate70$1,225
Ketoconazole59$1,086

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$511$153,46211 claims
NovartisCosentyx (2 Syringes)$204$100,99714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.

Other family in Vidalia

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →